Drug Trial Radar · NCT04533581
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Sep 17, 2020
Primary completion
May 31, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
Conditions
- Indolent B-cell Non-Hodgkin's Lymphoma
Interventions
ME-401Drug
In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to approximately 2 years
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Akita University Hospital
Akita, Japan
Aomori Prefectural Central Hospital
Aomori, Japan
Chiba Cancer Center
Chiba, Japan
Kyushu University Hospital
Fukuoka, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, Japan
Kagoshima University Hospital
Kagoshima, Japan
National Hospital Organization Kumamoto Medical Center
Kumamoto, Japan
Japanese Red Cross Kyoto Daini Hospital
Kyoto, Japan
Okayama University Hospital
Okayama, Japan
Anjo Kosei Hospital
Anjo, Aichi-ken, Japan
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan
Japanese Red Cross Nagoya Daini Hospital
Nagoya, Aichi-ken, Japan
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
Kameda Medical Center
Kamogawa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
Gunma University Hospital
Maebashi, Gunma, Japan
Chugoku Central Hospital
Fukuyama, Hiroshima, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Ishikawa Prefectural Central Hospital
Kanazawa, Ishikawa-ken, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Kurashiki Central Hospital
Kurashiki, Okayama-ken, Japan
Kindai University Hospital
Sayama, Osaka, Japan
Osaka University Hospital
Suita, Osaka, Japan
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
Jichi Medical University Hospital
Shimotsuke, Tochigi, Japan
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku, Tokyo, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital Of JFCR
Koto-ku, Tokyo, Japan
Tottori University Hospital
Yonago, Tottori, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.